Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 450.97 USD 0.13% Market Closed
Market Cap: 116.1B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

Vertex Pharmaceuticals Inc
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vertex Pharmaceuticals Inc
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Short-Term Investments
$1.3B
CAGR 3-Years
23%
CAGR 5-Years
17%
CAGR 10-Years
5%
Abbvie Inc
NYSE:ABBV
Short-Term Investments
$28m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Short-Term Investments
$1.7B
CAGR 3-Years
11%
CAGR 5-Years
16%
CAGR 10-Years
12%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Short-Term Investments
$7.8B
CAGR 3-Years
49%
CAGR 5-Years
39%
CAGR 10-Years
35%
No Stocks Found

Vertex Pharmaceuticals Inc
Glance View

Market Cap
116.2B USD
Industry
Biotechnology

Vertex Pharmaceuticals Inc. is a leading biotechnology company that has carved out a significant niche in the healthcare landscape, primarily focusing on the development of innovative treatments for serious diseases, particularly cystic fibrosis (CF). Founded in 1989 and headquartered in Boston, Massachusetts, Vertex has transformed the lives of patients with CF through its groundbreaking therapies that target the underlying causes of the disease rather than merely addressing symptoms. With a robust pipeline, the company continues to leverage its cutting-edge research capabilities to explore treatments for a range of other diseases, including pain and sickle cell disease, fostering a vision that extends beyond its current portfolio. For investors, Vertex stands out not only for its impressive track record of growth and profitability but also for its strategic partnerships and collaborations that enhance its research potential. The company’s flagship products, including Kalydeco and Trikafta, have seen substantial market success, establishing Vertex as a leader in the cystic fibrosis space. With strong financial performance signals—delivering consistent revenue growth and a commitment to reinvesting in R&D—investors can look forward to additional pipeline advancements, which may further bolster Vertex's market position. As healthcare continues to evolve, Vertex's unwavering focus on developing transformative therapies positions it as a compelling opportunity for those looking to invest in the future of biotechnology.

VRTX Intrinsic Value
254.13 USD
Overvaluation 44%
Intrinsic Value
Price

See Also

What is Vertex Pharmaceuticals Inc's Short-Term Investments?
Short-Term Investments
1.3B USD

Based on the financial report for Sep 30, 2024, Vertex Pharmaceuticals Inc's Short-Term Investments amounts to 1.3B USD.

What is Vertex Pharmaceuticals Inc's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
5%

Over the last year, the Short-Term Investments growth was 57%. The average annual Short-Term Investments growth rates for Vertex Pharmaceuticals Inc have been 23% over the past three years , 17% over the past five years , and 5% over the past ten years .

Back to Top